Know Cancer

or
forgot password

Evaluation of Polymorphisms and Mutations in Genes Postulated to Alter the Efficacy of Gefitinib in Samples From E1302


N/A
18 Years
N/A
Not Enrolling
Both
Head and Neck Cancer

Thank you

Trial Information

Evaluation of Polymorphisms and Mutations in Genes Postulated to Alter the Efficacy of Gefitinib in Samples From E1302


OBJECTIVES:

- To evaluate the frequency of ATP-binding cassette, sub-family G (WHITE), member 2
(ABCG2), met proto-oncogene (hepatocyte growth factor receptor) (c-MET), and v-Ki-ras2
Kirsten rat sarcoma viral oncogene homolog (K-ras) polymorphisms or mutations in this
study population and the predictiveness of these polymorphisms on survival, time to
progression, response rate, and toxicities.

OUTLINE: Archived tumor tissue and peripheral blood mononuclear cells are analyzed for the
frequency of ABCG2, c-MET, and K-ras polymorphisms or mutations by polymerase chain reaction
(PCR). Results are then correlated with patients' clinical outcomes and toxicity.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Patients diagnosed with recurrent or metastatic head and neck cancer treated on
Eastern Cooperative Oncology Group (ECOG)-E1302 trial

- Patients treated with docetaxel with versus without gefitinib

- Existing paraffin blocks and peripheral blood mononuclear cells

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

The prevalence of c-MET, ABCG2, and K-ras polymorphisms or mutation status summarized by frequency and percentage for all samples

Safety Issue:

No

Principal Investigator

Jill Kolesar, PharmD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Wisconsin, Madison

Authority:

Unspecified

Study ID:

CDR0000734898

NCT ID:

NCT01619618

Start Date:

May 2012

Completion Date:

Related Keywords:

  • Head and Neck Cancer
  • recurrent squamous cell carcinoma of the hypopharynx
  • stage IV squamous cell carcinoma of the hypopharynx
  • recurrent squamous cell carcinoma of the larynx
  • stage IVA squamous cell carcinoma of the larynx
  • stage IVB squamous cell carcinoma of the larynx
  • stage IVC squamous cell carcinoma of the larynx
  • recurrent squamous cell carcinoma of the lip and oral cavity
  • stage IVA squamous cell carcinoma of the lip and oral cavity
  • stage IVB squamous cell carcinoma of the lip and oral cavity
  • stage IVC squamous cell carcinoma of the lip and oral cavity
  • recurrent metastatic squamous neck cancer with occult primary
  • recurrent squamous cell carcinoma of the nasopharynx
  • stage IV squamous cell carcinoma of the nasopharynx
  • recurrent squamous cell carcinoma of the oropharynx
  • stage IVA squamous cell carcinoma of the oropharynx
  • stage IVB squamous cell carcinoma of the oropharynx
  • stage IVC squamous cell carcinoma of the oropharynx
  • recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
  • stage IVA squamous cell carcinoma of the paranasal sinus and nasal cavity
  • stage IVB squamous cell carcinoma of the paranasal sinus and nasal cavity
  • stage IVC squamous cell carcinoma of the paranasal sinus and nasal cavity
  • recurrent salivary gland cancer
  • stage IVA salivary gland cancer
  • stage IVB salivary gland cancer
  • stage IVC salivary gland cancer
  • Head and Neck Neoplasms

Name

Location